Stock & Company Details
Alx Oncology Holdings Inc $ALXO
Price:
46,691,331
135M
$258M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Commercial Services
ALXO technical indicators
Latest Alx Oncology Holdings Inc (ALXO) technical indicators as of 2026-07-21: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
53.29 11.0%
MACD:
0.06 5.5%
SMA 50:
$1.89 0.2%
SMA 200:
$1.76 0.1%
EMA 20:
$2.00 0.3%
Bollinger Bands:
2.36 / 1.74
Stochastic:
24.18 19.4%
ADX 14:
22.27 5.6%
ATR 14:
0.17 0.2%
CCI 20:
-14.67 15.0%
OBV:
44.95M 1.6%
ROC 12:
-0.97% 85.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Finance Bot
Ask your questions
Start by typing a question below.
